MOLOGEN AG
MOLOGEN AG: Grant to collaboration partner for combination study in HIV with lead product lefitolimod
DGAP-News: MOLOGEN AG / Key word(s): Alliance/Study PRESS RELEASE N 1 / 2017 of 01/10/2017 MOLOGEN AG: Grant to collaboration partner for combination study in HIV with lead product lefitolimod – Gilead Sciences, Inc. grant for Aarhus University Hospital – Funding for a novel “kick-and-kill” concept of HIV eradication – Lefitolimod to be combined with new virus-neutralizing antibodies
Dr. Mariola Söhngen, CEO of MOLOGEN, said: “In addition to our ongoing TEACH study this innovative approach could help us to further evaluate the potential of lefitolimod in HIV. Lefitolimod would be combined with novel antibodies. Due to its mode of action we strongly believe that the combination of different compounds could be of benefit in a number of patients.” New approach of the “kick-and-kill” concept HIV infects the immune system and destroys or affects the proper function of immune cells. Without antiretroviral treatment, this eventually leads to acquired immune deficiency syndrome (AIDS) and the immune system can no longer fend off a wide range of infections and diseases. HIV remains a serious worldwide health issue. According to estimates by WHO and UNAIDS (United Nations Programme on AIDS) 37 million people worldwide were living with HIV at the end of 2015. Some 2 million people became newly infected in that same year, and 1.1 million died as a result of HIV-related causes globally. MOLOGEN AG The cancer immunotherapy lefitolimod (MGN1703) is the company’s lead product and best-in-class TLR9 agonist. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mode of action, namely to reactivate the monitoring function of the immune system, lefitolimod (MGN1703) can be recognized as an Immune Surveillance Reactivator (ISR). It has the potential to be applied to various indications. ISR lefitolimod (MGN1703) is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore, it is also being investigated in an extended phase I study in HIV and a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)). Next to checkpoint inhibitors, lefitolimod is one of the few product candidates that are in a phase III clinical trial (IMPALA) in the field of immuno-oncology and close to reaching the market. MOLOGEN’s pipeline focus is on new, innovative immunotherapies to treat diseases for which there is a high medical need. Memberships in associations: MOLOGEN(R), dSLIM(R), EnanDIM(R) and MIDGE(R) are registered trademarks of MOLOGEN AG. Note about risk for future predictions
10.01.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | MOLOGEN AG |
Fabeckstraße 30 | |
14195 Berlin | |
Germany | |
Phone: | 030 / 841788-0 |
Fax: | 030 / 841788-50 |
E-mail: | presse@mologen.com |
Internet: | www.mologen.com |
ISIN: | DE0006637200 |
WKN: | 663720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |